ACAD - Company ID 0001070494
The table below shows ACADIA PHARMACEUTICALS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $307.96M | $268.06M | $278.63M | $264.57M | $244.32M | $250.40M |
| Cost of revenue | $28.32M | $24.79M | $21.65M | $20.73M | $20.39M | $18.86M |
| Gross profit | - | - | - | - | - | - |
| R&D | $81.56M | $76.87M | $87.83M | $77.95M | $78.27M | $66.61M |
ACADIA PHARMACEUTICALS INC reported annual revenue of $1.07B for fiscal year 2025. That is up 11.9% from $957.80M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $17.33M (FY 2016) to $1.07B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $160.25M |
| $171.02M |
| $133.40M |
| $133.51M |
| $126.37M |
| $133.29M |
| Operating income | $37.84M | -$4.62M | $35.76M | $32.37M | $19.29M | $31.64M |
| Income tax | $14.97M | $344.00K | -$27.18M | $13.54M | $8.79M | $6.04M |
| Net income | $31.50M | $3.64M | $71.78M | $26.67M | $18.99M | $32.77M |
| EPS (diluted) | $0.18 | $0.02 | $0.42 | $0.16 | $0.11 | $0.20 |